Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

Simbarashe Takuva(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Michal Juraska(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Robert De La Grecca(Infectious Disease Research Institute), Srilatha Edupuganti(Emory University), Myron S. Cohen(University of North Carolina at Chapel Hill), Stephen R. Walsh(Beth Israel Deaconess Medical Center), Carissa Karg(Infectious Disease Research Institute), Catherine Orrell(South African Medical Research Council), April K. Randhawa(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Maija Anderson(Fred Hutch Cancer Center), Javier Valencia(Asociación Civil Impacta Salud y Educación), Alice Sehurutshi(Botswana Harvard AIDS Institute Partnership), Martin R. Gaudinski(National Institute of Allergy and Infectious Diseases), Erika Rudnicki(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Margarita M. Gomez Lorenzo(Norwegian Womens Public Health Association), Lawrence Corey(Fred Hutch Cancer Center), Larissa M. Villela(Fundação Oswaldo Cruz), Shelly Karuna(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), John R. Mascola(National Institute of Allergy and Infectious Diseases), Kathryn Mngadi(Aurum Institute), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), P. Andrew(Family Health International 360), David Burns(Norwegian Womens Public Health Association), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nyaradzo Mgodi(University of Zimbabwe), Logashvari Naidoo(South African Medical Research Council)
JAIDS Journal of Acquired Immune Deficiency Syndromes
December 20, 2021
Cited by 11


Related Papers